GlassScriptPhysician profile
Rosemary Yi
NPI 1871804880
$3,995.78
in general payments reported to CMS, 2019-2025
11 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,619 · 2020: $217 · 2021: $570 · 2022: $1,170 · 2023: $24.19 · 2024: $240 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $419.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Encore Medical, LP | $2,541.58 | 2019-2022 | |
| Stryker Corporation | $650.75 | 2019-2025 | Gamma, Insignia, Triathlon |
| Dynasplint Systems INC. | $285.40 | 2021 | |
| Integra Lifesciences Corporation | $160.59 | 2019-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Axogen | $148.48 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $57.31 | 2019-2021 | |
| Depuy Synthes Sales INC. | $43.63 | 2020 | |
| Heron Therapeutics, INC. | $42.14 | 2022 | |
| Ethicon US, LLC | $26.99 | 2025 | Vistaseal, Surgiflo Hemostatic Matrix, Ethicon |
| Medartis INC. | $22.79 | 2020 | |
| Bioventus LLC | $16.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosemary Yi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.